SecBot SecBot
8-K ·Filed May 22, 2026

CRIS

CURIS INC
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001108205-26-000065
8-K context-dependent: Items 3.03
Actionable Insight ▼ Bearish

The authorized share increase is a near-term dilutive signal for a micro-cap biotech, watch for an overnight S-3 shelf filing or registered direct offering in coming weeks. The Series B conversion in March already added ~20M shares of overhang; this filing clears deck for further financing. Monitor for any ATM program or public offering announcement.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.80
T+0 close · May 22, 2026 · via day close
Latest settled
−82.45%
T+60 · $1.72
Vs SPY
−85.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $9.80entry
  2. T+1 · 6mo ago +8.16%α +8.18% · $10.60
  3. T+5 · 6mo ago +2.04%α +0.84% · $10.00
  4. T+20 · 5mo ago −30.61%α −28.55% · $6.80
  5. T+60 · 3mo ago −82.45%α −85.17% · $1.72

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Curis Inc. shareholders approved a charter amendment at the May 19, 2026 annual meeting to nearly double authorized common shares from 283.8M to 567.5M, providing substantial future dilution capacity. Simultaneously, the company eliminated the Certificate of Designations for its Series A and B Preferred Stock, returning those shares to undesignated authorized preferred status. For a micro-cap biotech with a ~$19M market cap, the massive authorized share increase signals potential future capital raises, but no immediate offering is announced.

Key Facts

  • Authorized common shares increased from 283,757,150 to 567,514,300 (near-doubling).
  • Total authorized capital stock increased from 288,757,150 to 572,514,300 shares.
  • Series A and Series B Preferred Stock certificate of designations eliminated; preferred shares returned to undesignated authorized status.
  • All proposals at the Annual Meeting passed, including director elections, executive compensation (non-binding), auditor ratification, and the share increase.
  • Series B Preferred Stock (20,195 shares) had been auto-converted to common and pre-funded warrants in March 2026.
  • Current market cap is ~$19M; the company is a pre-revenue clinical-stage biotech.

Financial Impact

Authorized common shares nearly doubled to 567.5M shares; no immediate pricing or offering attached. The company now has capacity to issue over 280M additional shares.

dilutioncapitalization

Risk Factors

  • Substantial future dilution from the ~284M newly authorized but unissued common shares.
  • Potential near-term equity financing given micro-cap capitalization and clinical-stage pipeline needs.
  • No revenue disclosed; cash runway not stated, financing likely needed for operations.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001108205-26-000065
Document: cris-8xk_exh32xcertificate.htm0001108205-26-000065
Document: cris-8xk_exh31xcharteramen.htm0001108205-26-000065
Document: 0001108205-26-000065-index-headers.html0001108205-26-000065
Document: 0001108205-26-000065-index.html0001108205-26-000065
Document: 0001108205-26-000065.txt0001108205-26-000065

Track record

18 reports on CRIS

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +57.07% at T+60 after the May 1, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
  4. Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
  5. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
  6. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
  7. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
  8. Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
  9. Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
  10. Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026